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Antibiotic resistance is a global health crisis that requires urgent action to stop its spread. To 
counteract the spread of antibiotic resistance, we must improve our understanding of the origin and 
spread of resistant bacteria in both community and healthcare settings. Unfortunately, little attention 
is being given to contain the spread of antibiotic resistance in community settings (i.e., locations 
outside of a hospital inpatient, acute care setting, or a hospital clinic setting), despite some studies 
have consistently reported a high prevalence of antibiotic resistance in the community settings. 
This study aimed to investigate the prevalence of antibiotic resistance in commensal Escherichia coli 
isolates from healthy humans in community settings in LMICs. Using the Preferred Reporting Items for 
Systematic Reviews and Meta‑Analyses (PRISMA) guidelines, we synthesized studies conducted from 
1989 to May 2020. A total of 9363 articles were obtained from the search and prevalence data were 
extracted from 33 articles and pooled together. This gave a pooled prevalence of antibiotic resistance 
(top ten antibiotics commonly prescribed in LMICs) in commensal E. coli isolates from human sources 
in community settings in LMICs of: ampicillin (72% of 13,531 isolates, 95% CI: 65–79), cefotaxime 
(27% of 6700 isolates, 95% CI: 12–44), chloramphenicol (45% of 7012 isolates, 95% CI: 35–53), 
ciprofloxacin (17% of 10,618 isolates, 95% CI: 11–25), co‑trimoxazole (63% of 10,561 isolates, 95% 
CI: 52–73), nalidixic acid (30% of 9819 isolates, 95% CI: 21–40), oxytetracycline (78% of 1451 isolates, 
95% CI: 65–88), streptomycin (58% of 3831 isolates, 95% CI: 44–72), tetracycline (67% of 11,847 
isolates, 95% CI: 59–74), and trimethoprim (67% of 3265 isolates, 95% CI: 59–75). Here, we provided 
an appraisal of the evidence of the high prevalence of antibiotic resistance by commensal E. coli in 
community settings in LMICs. Our findings will have important ramifications for public health policy 
design to contain the spread of antibiotic resistance in community settings. Indeed, commensal E. coli 
is the main reservoir for spreading antibiotic resistance to other pathogenic enteric bacteria via mobile 
genetic elements.
Antibiotic resistance (ABR) is currently identified as one of the biggest threats to not only global health but also 
to food security and  development1. Resistance occurs when the antibiotics (medicines used to prevent and treat 
bacterial infections) are no longer effective at inhibiting the growth of the  bacteria1. There is a growing increase 
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of resistance by bacteria to  antibiotics2–10 with the World Health Organization (WHO) through its Global Anti-
microbial Surveillance System (GLASS) report revealing that there are high levels of antibiotic resistance in both 
low- and high-income  countries11. In fact, the European Centre for Disease Prevention and Control (ECDC) 
reported that 25,000 people died of diseases caused by antibiotic-resistant bacteria in 2007, which is over half 
the number caused by road traffic accidents in the same  countries12. In 2015, this number increased to about 
33,000 deaths resulting from an estimated 671,689 infections of selected antibiotic-resistant bacteria leading 
to 874,541 total disability-adjusted life-years (DALYs)13. This indicates that the burden in the European Union 
and European Economic Area is on the rise. Likewise, the World Health Organization (WHO) predicted that 
by 2050, the number of people who will die due to antibiotic resistance would increase from 700,000 to about 
10 million per year  globally14. As a result of antibiotic resistance, more than 2.8 million people are infected, and 
more than 35,000 die each year in the  USA15,16.
The burden caused by antibiotic resistance is greater in low- and middle-income countries (LMICs) whose 
health care systems are poor and lack tools to perform rapid diagnosis of the numerous neglected infectious 
 diseases17. In the community settings in LMICs, high prevalence of multidrug-, extensive drug-, and pan drug-
resistant commensal Escherichia coli isolated from healthy humans has been  reported18. Thus, greater efforts 
should be placed in LMICs to contain the spread of antibiotic-resistant E. coli, especially with its relaxed anti-
biotics prescription policies. Antibiotic resistance has led to an increase in poverty in  LMICs16, and antibiotics 
misuse is associated with the carriage of resistant commensal E. coli from healthy children in community settings 
 worldwide19,20. In high-income countries, stringent antibiotic prescription policies are in place to reverse the 
course of antibiotic  resistance21.
Commensal Escherichia coli is a gram-negative bacterium located in the gut of humans, animals, birds, and 
also exists in the  environment22. It is a pathogen on the WHO global critical pathogen priority list for research, 
discovery, and new antibiotics  development23. When we ingest antibiotics for the treatment of bacterial infec-
tions, the commensal E. coli is exposed to these antibiotics and can develop resistance to these antibiotics through 
natural  selection24. Indeed, commensal E. coli is one of the major reservoirs for the transmission of antibiotic 
resistance to other pathogenic bacteria through plasmid exchange, for example (Fig. 1)25–32. Humans can be 
exposed to viable commensal antibiotic-resistant E. coli by contact with livestock or a contaminated natural 
environment and by inadequately cooked food or cross-contamination33–35.
Many studies have shown a high prevalence of resistance to antibiotics by pathogenic and commensal bac-
teria in healthcare  settings8. However, when comparing these studies to those conducted in community settings 
there is a large discrepancy, especially in  LMICs36. This is as a result of the fact that little attention is given at 
Figure 1.  Transfer of resistance between bacteria through plasmid exchange. (a) Commensal E. coli, pathogenic 
E. coli and other pathogenic bacteria come together in the gut, (b) Bacteria attached and exchanged plasmids 
conferring antibiotic resistance. (c) Bacteria-acquired resistant plasmids.
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the community level to contain the global antibiotic resistance crises; despite some studies that compare the 
prevalence of resistance to antibiotics in both communities and hospitals all showed consistently high values 
with no significant  difference8,22,37–40. Thus, similar attention should be given to contain the cause of resistance 
to antibiotics by bacteria in communities, as is the case in hospitals. If this situation is not addressed, many of 
the gains in modern medicine will be lost and the commitment to achieve universal health coverage by world 
leaders will be in  vain7,41. In this paper, we aim to provide an appraisal of the evidence of the high prevalence 
of antibiotic resistance by commensal E. coli to commonly prescribed antibiotics in community settings (i.e., 
locations outside the hospital such as homes and schools) in LMICs to bring to light the extent of the problem 
and inform interventions targeted at controlling and preventing antibiotic resistance. Indeed, a multitude of 
knowledge, attitudes, and practices (KAP), education, and community engagement interventions exist in com-
munity settings in low- and middle-income countries (LMICs), yet data to support and justify their set-up are 
often lacking. Thus, our data should prove useful to support the course for the fight against antibiotic resistance 
by researchers, community pharmacists, public health policymakers, advocacy groups, farmers, among others. 
A collective approach involving every country to fight antibiotic resistance is crucial to reduce the mortality, 
morbidity, associated health and healthcare costs, and the spread of resistant  bacteria10,42.
Results
Literature search. A total of 9363 articles were obtained from the search (PubMed = 3634, EMBASE + MED-
LINE = 2103, Web of Science = 3046, CINAHL = 290 and Cochrane Library = 289). Out of the 9363 articles, 2280 
duplicates were removed using EndNote X8. We screened 7089 articles to identify article hits that met our 
inclusion criteria (Fig. 2). We performed a full-text screening of 53 studies and data were extracted from 33 
 articles8,28,29,43–72. A total of 20 articles in which the isolates were pathogenic (14), were collected in a high-
income country (3), could not be obtained online (2), or review articles (1) were excluded for data extraction.
Study location, strength of evidence, and study type. Out of the 33 included studies, 10 were from 
Africa, 13 from Asia, 1 from Europe, 8 from South America, and 1 from multiple locations (Fig. 3a,d). The qual-
ity of the evidence was assessed as described  previously74,75. Of the 33 studies, 16 were marked as high quality, 
Figure 2.  Flow diagram of the literature search  strategy73. Additional records were identified from the reference 
lists of some of the included studies.
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16 as a medium, and 1 as low quality (Fig. 3b). These included studies were cross-sectional (25), cohort (6), 
case–control (1), and double-blind randomized control trials (1) (Fig. 3c).
Age, sample size, and gender. The included studies comprise of about 7755 health individuals in com-
munity settings from 0 to 77 years of age from 1989 to 2019. One limitation of this study is that some articles did 
not record the number of males and females, thus it was challenging to determine the ratio of males to females. 
However, we calculated the number of males and females using the studies that recorded the numbers. Of these 
studies, 2443 were males and 2010 were females. Thus, assuming a total population of 7755, we extrapolated the 
number of males to be 4255, and females 3500.
High prevalence of antibiotic resistance in the community settings will potentially impact 
health policy. The pooled prevalence of commensal E. coli isolated from healthy individuals in community 
settings in LMICs for the different antibiotics are summarized in Table 1, Fig. 4, and Supplementary Fig. 1. A 
high prevalence was seen for some of the commonly prescribed antibiotics in these countries like ampicillin 
(72%, 95% CI: 65–79), cefotaxime (27%, 95% CI: 12–44), chloramphenicol (45%, 95% CI: 35–53), ciprofloxacin 
(17%, 95% CI: 11–25), co-trimoxazole (63%, 95% CI: 52–73, nalidixic acid (30%, 95% CI: 21–40), oxytetra-
cycline (78%, 95% CI: 65–88), streptomycin (58%, 95% CI: 44–72), tetracycline (67%, 95% CI: 59–74), and 
trimethoprim (67%, 95% CI: 59–75). These findings will be very useful for evidence-based health policy design 
aimed at combating the spread of antibiotic resistance in the community.
Prevalence of antibiotic resistance data of a plethora of antibiotics will potentially impact 
antibiotic stewardship programs. In this study, the prevalence of resistance was collected for a range 
of diverse antibiotics and mechanisms of actions such as, inhibition of protein, nucleic acid, folic acid, or cell 
wall synthesis. For some antibiotics, the resistance was very high, others were emerging, and for some it was 
low (Table 1 and Supplementary Table 4). This evidence should prove useful to inform antibiotic stewardship 
programs.
Investigating the source of heterogeneity. The results show a high  I2 value, which indicates consid-
erable heterogeneity. Funnel plots and Egger’s regression test was used to explore the sources of heterogeneity. 
Figure 3.  Characteristics of the included studies. (a) Location, (b) quality of the evidence, and (c) type of 
studies. (d) World map showing the number of studies by continents. The world map was obtained from (https 
://yourf reete mplat es.com/) on 17th December 2020.
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The funnel plots for all antibiotics were asymmetrical (Supplementary Fig. 2), thus indicating a possibility of 
publication bias. We further investigate the existence of publication bias per antibiotic using Egger’s regression 
test (Supplementary Table  5). Most of the antibiotics (ampicillin, cefotaxime, co-trimoxazole, nalidixic acid, 
streptomycin, and trimethoprim) did not exhibit publication bias. The antibiotics that exhibited publication bias 
were chloramphenicol, ciprofloxacin, oxytetracycline, and tetracycline. On further stratification of each antibi-
otic prevalence, according to continents (Africa, South America, and Asia), there was a reduced likelihood of 
publication bias based on visual examination of the funnel plot.
Discussion
Antibiotic resistance (ABR) is a serious global health threat that needs to be addressed  urgently2–8. ABR’s impact 
is particularly greater in low- and middle-income countries (LMICs), which bear the highest-burden and subse-
quently suffer the most from this problem, primarily because their healthcare systems lack the resources needed 
to contain or to treat challenging infectious diseases caused by drug-resistant  bacteria17. Indeed, it has led to 
an increase in poverty in  LMICs16. While there has been a general increase in multidrug-resistant pathogenic 
bacteria in community  settings77 recent evidence suggests that the prevalence of multidrug-resistant commensal 
Escherichia coli isolated from healthy individuals is particularly high in  LMICs18. In this study, we synthesized 
a total of 33 articles to obtain a pooled prevalence of ABR in the top ten antibiotics commonly prescribed in 
community settings (i.e., locations outside of a hospital, such as schools and homes) in LMICs.
There are several factors that contribute to  ABR78, with a complicated inter-relationship that spans across 
different sectors outside of healthcare alone, such as agriculture and industry. Among the main factors identi-
fied leading to resistance in commensal E. coli in LMICs are overcrowding, poverty, socioecological behaviours, 
food and supply chain safety issues, highly contaminated waste effluents and inadequate surveillance  systems79. 
Nevertheless, the primary driver of multidrug-resistance in LMICs has been misuse and over-prescription of 
 antibiotics80. Commensal E. coli are typically present in the guts of humans, animals, birds, as well as in the 
environment, and can develop resistance to antibacterial agents through natural selection when ingested for the 
treatment of bacterial  infections22,24.
This review revealed a high prevalence of antibiotic resistance in commensal E. coli to the most prescribed 
antibiotics in LMICs. Moreover, this was a consistent finding across several classes of antibiotics with different 
mechanisms of action. For instance, the pooled prevalence of antibiotic resistance for the β-lactam antibiotic 
ampicillin was 72%, 95% CI: 65–79, while for trimethoprim, a folic acid synthesis inhibitor, the pooled prevalence 
was 67%, 95% CI: 59–75. Similar observations were reported in a recent systematic review investigating ABR in 
E. coli strains isolated from humans, animals, food, and the environment in several middle- and high-income 
Table 1.  Prevalence of antibiotic resistance in commensal E. coli isolated from human sources in community 
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countries. The authors presented high rates of resistance against a range of antibiotics found in E. coli isolates, 
although the pooled prevalence was generally lower than in the isolates from healthy individuals from LMICs 
presented  here81. For ciprofloxacin, the pooled prevalence from our study was 17%, 95% CI: 11–25, which is in the 
range of the resistance seen for treating E. coli associated urinary tract infection (8% to 65%)11, and other E. coli 
isolated from farmed minks in Zhucheng,  China76. Likewise, for cotrimoxazole, our data (63%, 95% CI, 52–73) 
agrees with another study carried out in Zimbabwe, where the prevalence was 68% for Gram-negative  bacillli82. 
The main limitation of our study is the fact that the heterogeneity between studies was very high (Table 1, Fig. 4). 
We performed an additional statistical analysis stratified by continent. The goal was to solve the heterogeneity 
issue, however, there was no significant difference between the pooled prevalence of antibiotic resistance values 
between continents. The high heterogeneity between studies could stem from the different factors associated 
with the carriage resistant commensal E. coli in LMICs highlighted in the discussion section above. Since  I2 sta-
tistics test for heterogeneity can be misleading during meta-analysis of observational  studies83,84, we performed 
an alternative assessment of the strength of evidence of the different studies (supplementary table 3)74,75. The 
included studies utilized disc diffusion or synergy test to investigate the expression of resistant genes in the 
presence of antibiotics. However, those that employed an additional method, such as PCR, plasmid transfer 
assay, nucleic acid identification, mass spectrometry, to validate the presence of genes conferring resistance to a 
particular antibiotic were graded as high.
Our study is in line with the WHO’s Global action plan on antimicrobial resistance, which calls for improved 
awareness of the problems arising from antibiotic resistance as stated in one of the five strategic  objectives85. 
Indeed, raising awareness can be facilitated, for example, through the making of participatory  videos86. As 
expected, in this study, resistance was commonly detected from stool samples collected from healthy volunteers 
in community settings. Our findings have important ramifications for public health policies and antibiotic 
resistance stewardship through a one-health approach for the fight against ABR. In some of the studies screened, 
Figure 4.  Forest plots showing the prevalence of antibiotic resistance in commensal E. coli isolated from 
human sources in community settings in low- and middle-income countries. (a) Cell wall synthesis inhibitor 
(ampicillin), (b) protein synthesis inhibitor (tetracycline), (c) folate synthesis inhibitor (co-trimoxazole), and (d) 
nucleic acid synthesis inhibitor (ciprofloxacin).
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factors such as previous antibiotic  use19,55,59,65, geographical  location8,57,  age8,59, socioeconomic  status43,55,57, and 
exposure to  animals49,65 were highlighted as being associated with a high prevalence of resistance. The situation 
is even more pressing with the emergence of global pandemics such as the coronavirus disease 2019 (COVID19) 
caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)87. Prior to the availability of 
approved vaccines, different medicines have been tested randomly in clinical trials to find a cure for this deadly 
 pandemic87–94. Since viral infections are often associated with bacterial  infections95,96, the antibiotic azithromycin 
in combination with the antimalarial drug hydroxychloroquine was proposed as an option for the treatment of 
COVID19  patients97. Thus, we may see a post-COVID19 global health crisis with a surge in antibiotic resistance 
leading to many  deaths97.
Conclusion
This study provides further evidence of the high prevalence of antibiotic resistant commensal E. coli from healthy 
human sources in community settings in LMICs. These findings should encourage health researchers, medical 
professionals, advocacy groups, and health policymakers to work together to develop appropriate interventions 
to counteract this growing global health threat. We recommend that the strategies that have been implemented in 
healthcare settings to contain the spread of resistance, such as surveillance, raising awareness, improve sanitation 
and hygiene, rapid diagnosis of diseases, and stringent prescription policies should also be urgently implemented 
in the communities to curb antibiotic resistance.
Methods
Design. A systematic approach was used to retrieve and synthesize studies that met our inclusion criteria 
following PRISMA  guidelines73.
Type of studies. The types of studies included in the systematic review are those in which the main outcome 
was the prevalence of antibiotic resistance in commensal Escherichia coli: cross-sectional, case–control, cohort 
studies, and randomized control trials.
Type of participants (study population). This review included studies concerning the general healthy 
populations in community settings in LMICs.
Outcome of interest. 
• The primary outcome was prevalence of resistance to antibiotic by commensal E. coli in community settings 
in LMICs.
• The secondary outcomes were: odds ratio, risk ratio, rate, 95% confidence interval, and p-value.
Other inclusion and exclusion criteria. Articles written in English language were included from 1989 
to May 2020 in LMICs. Articles containing studies conducted in a country that was classified as a LMIC before 
transforming into a high-income country according to the World Bank definition were also included. The 
included studies must investigate the resistance of commensal E. coli on either solid or liquid growth media in 
the presence of antibiotics.
Essential data necessary for inclusion. Studies were eligible for inclusion if they reported at least one of 
the primary or secondary outcomes listed in the outcome of interest section above.
Data sources. Published data from PubMed, EMBASE, MEDLINE, Web of Science, CINAHL and Cochrane 
Library, reference lists of selected studies and unpublished data such as abstracts from Conference proceedings; 
dissertations and theses were the data sources.
Systematic search strategy. A literature search was performed on the 10th of March 2018 and was 
updated on the 18th of May 2020. Briefly, we searched PubMed, EMBASE, MEDLINE, Web of Science, CINAHL, 
and Cochrane Library using MeSH terms for PubMed and the comparable terms for the other databases. The 
search terms were “E. coli OR Escherichia coli OR Enterobacteriaceae” AND "antibiotic resistance OR antimicro-
bial resistance OR drug resistance” AND "prevalence OR incidence OR morbidity OR odd ratio OR risk ratio OR 
confidence interval OR p-value OR rate". For PubMed, EMBASE, and MEDLINE, studies performed in humans 
were selected using the Species filters. While for Web of Science and Cochrane Library additional search words 
were added to select for species (human* OR infant* OR child* OR adolescen* OR male* OR female OR age 
OR adult*) since there was no sorting filter for species. For CINAHL, no selection for species was performed. 
Search words were designed from the different categories in the PICO (Population, Intervention, Comparison, 
and Outcome) format. Details of the search terms used are summarized in Supplementary Table 1. The arti-
cles obtained from the search were exported to EndNote for duplicate removal. The unique hits were further 
exported to Rayyan QCRI website for screening and data  extraction98. An initial screening was performed by 
title and abstract, followed by full article text.
Data extraction and quality assessment. A two-step process was followed involving screening of titles 
and abstracts to identify relevant articles, which was followed by full-text reading of the relevant articles. A 
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total of 53 full-text articles were screened, and the data extracted and recorded on an excel spreadsheet by five 
researchers. To exclude selection bias, a sixth researcher was available to solve the disagreements that arose 
during the data extraction. The parameters that were extracted are listed in Supplementary Table 2. The quality 
of evidence in the included studies was assessed as described  before72,73 (Supplementary Table 3). In brief, stud-
ies that utilized disc diffusion or synergy test in combination with one of the following biochemical test such 
as, polymerase chain reaction (PCR), plasmid transfer assay (PTA), pulsed-field gel electrophoresis (PFGE), 
nucleic acid sequencing, and mass spectrometry to detect the presence of resistant genes was graded as high. 
Furthermore, studies which use only disc diffusion of synergy test with a sample size less than 15 were classified 
as medium. Lastly, studies which sample size of below 15 and utilized only disc diffusion or synergy test were 
classified as low.
Statistical analysis. Statistical analysis was performed in  Stata99 and JBI  SUMARI100. The prevalence of 
antibiotic resistance of commensal E. coli was defined as the proportion of the isolates in a specific study that 
were found to be resistant to a given antibiotics presented as a percentage. The pooled prevalence was calculated 
using the metaprop command in  Stata101. Metaprop pools proportions and presents a weighted sub-group and 
overall pooled estimates with inverse-variance weights obtained from a random-effects model. In this case, it 
involved a meta-analysis of the prevalence values of the individual publications weighted on sample size while 
accounting for potential heterogeneity between studies. For JBI SUMARI, proportional meta-analysis was calcu-
lated using the random-effects model of Freeman-Tukey transformation. Besides, a forest plot was constructed 
for each of the top ten most reported antibiotics in our study.
The source of heterogeneity was explored by stratifying the pooled prevalence by year of sample analysis 
(study period), geographical location (continents), and type of antibiotic. Funnel plots of overall effect size were 
run to determine the existence of publication bias by visual inspection. Also, the Egger’s test was used to assess 
the occurrence of small size effect. The level of significance was maintained at 0.05.
Data availability
Data related to the manuscript is available upon request to corresponding author.
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